{"id":"https://openalex.org/W2474380585","doi":null,"title":"Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.","display_name":"Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.","publication_year":2016,"publication_date":"2016-06-01","ids":{"openalex":"https://openalex.org/W2474380585","mag":"2474380585","pmid":"https://pubmed.ncbi.nlm.nih.gov/27688833","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5004818"},"language":"en","primary_location":{"id":"pmh:oai:europepmc.org:3994910","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5004818","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5004818","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013186562","display_name":"S Pinar Bilir","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S Pinar Bilir","raw_affiliation_strings":["Director, Health Economics and Outcomes Research, IMS Health, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Director, Health Economics and Outcomes Research, IMS Health, San Francisco, CA","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112646814","display_name":"Qiufei Ma","orcid":"https://orcid.org/0000-0003-4270-3487","observed_orcids":["https://orcid.org/0000-0003-4270-3487"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qiufei Ma","raw_affiliation_strings":["Senior Manager, Amgen, Thousand Oaks, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Senior Manager, Amgen, Thousand Oaks, CA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102740767","display_name":"Zhongyun Zhao","orcid":"https://orcid.org/0000-0003-4306-5202","observed_orcids":["https://orcid.org/0000-0003-4306-5202"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhongyun Zhao","raw_affiliation_strings":["Director, Amgen"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Director, Amgen","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021326375","display_name":"Elizabeth Wehler","orcid":"https://orcid.org/0000-0001-5059-882X","observed_orcids":["https://orcid.org/0000-0001-5059-882X"]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Wehler","raw_affiliation_strings":["Senior Consultant, Health Economics and Outcomes Research, IMS Health, Plymouth Meeting, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Senior Consultant, Health Economics and Outcomes Research, IMS Health, Plymouth Meeting, PA","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108507039","display_name":"Julie Munakata","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julie Munakata","raw_affiliation_strings":["General Manager, Medical and Scientific Services, Health Economics and Outcomes Research, IMS Health, San Francisco"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"General Manager, Medical and Scientific Services, Health Economics and Outcomes Research, IMS Health, San Francisco","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108620199","display_name":"Beth Barber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Beth Barber","raw_affiliation_strings":["Executive Director, Amgen"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Executive Director, Amgen","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":12.0282,"has_fulltext":false,"cited_by_count":38,"citation_normalized_percentile":{"value":0.98252463,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"9","issue":"4","first_page":"203","last_page":"13"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9959999918937683},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.8690000176429749},{"id":"https://openalex.org/keywords/economic-burden","display_name":"economic burden","score":0.6690000295639038},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7390000224113464},{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":0.9240000247955322},{"id":"https://openalex.org/keywords/dabrafenib","display_name":"dabrafenib","score":0.996999979019165},{"id":"https://openalex.org/keywords/trametinib","display_name":"trametinib","score":0.9660000205039978},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/talimogene-laherparepvec","display_name":"talimogene laherparepvec","score":0.9800000190734863},{"id":"https://openalex.org/keywords/cutaneous-squamous-cell-carcinoma","display_name":"cutaneous squamous cell carcinoma","score":0.8840000033378601},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8939999938011169},{"id":"https://openalex.org/keywords/hospitalization-costs","display_name":"hospital costs","score":0.765999972820282},{"id":"https://openalex.org/keywords/outpatient-costs","display_name":"outpatient costs","score":0.7099999785423279},{"id":"https://openalex.org/keywords/chemotherapy-toxicity","display_name":"chemotherapy toxicity","score":0.3009999990463257}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9218461513519287},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.7567048072814941},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.5916218757629395},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5728110074996948},{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.5305042266845703},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.5132360458374023},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5094950795173645},{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.5074736475944519},{"id":"https://openalex.org/C2778830669","wikidata":"https://www.wikidata.org/wiki/Q3011604","display_name":"Dabrafenib","level":5,"score":0.49554479122161865},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4902065396308899},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4309479594230652},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.42211493849754333},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.41142815351486206},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3322173058986664},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.14502346515655518},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.11531436443328857},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.11405590176582336},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.09609231352806091},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.0},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:oai:europepmc.org:3994910","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5004818","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:27688833","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27688833","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American health & drug benefits","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5004818","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5004818/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Am Health Drug Benefits","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:3994910","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5004818","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W1965370740","https://openalex.org/W1994640169","https://openalex.org/W2040851929","https://openalex.org/W2097995306","https://openalex.org/W2109274792","https://openalex.org/W2109291025","https://openalex.org/W2123363005","https://openalex.org/W2128542677","https://openalex.org/W2136474966","https://openalex.org/W2155777530","https://openalex.org/W2162357591","https://openalex.org/W2166262263","https://openalex.org/W2166662937","https://openalex.org/W2168143310","https://openalex.org/W2168711434","https://openalex.org/W2314561197","https://openalex.org/W2572174216"],"related_works":["https://openalex.org/W2209218670","https://openalex.org/W2109291025","https://openalex.org/W6958386090","https://openalex.org/W2886326580","https://openalex.org/W2102250468","https://openalex.org/W1995750100","https://openalex.org/W2908105704","https://openalex.org/W2314561197","https://openalex.org/W2077708494","https://openalex.org/W2335660606"],"abstract_inverted_index":{"BACKGROUND:":[0],"Little":[1],"has":[2],"been":[3],"reported":[4],"on":[5],"the":[6,10,39,47,76,96,105,113,125,138,162,172,216,275,369,378,383,395],"costs":[7,41,129,154,270,292,331,341,370,384],"of":[8,42,59,78,82,107,110,174,342,397],"managing":[9,343,398],"adverse":[11],"events":[12],"(AEs)":[13],"associated":[14,40,56,133,159,187,202,220,233,328,371],"with":[15,20,33,57,120,134,188,203,221,234,242,262,329,348,355,372,400],"current":[16],"therapies":[17],"for":[18,54,104,130,157,171,191,271,279,293,297,332,368],"patients":[19,32,347,399],"regional":[21],"or":[22,209,247,311,319],"distant":[23],"metastatic":[24,34,60,349,401],"melanoma.":[25,402],"OBJECTIVES:":[26],"To":[27],"identify":[28],"treatment-related":[29,344],"AEs":[30,45,55,74,186,201,219,241,345],"in":[31,46,91,112,124,137,274,346,377,386],"melanoma":[35,61,122,135,192,350],"and":[36,72,85,95,152,196,212,227,236,284,302,323,380],"to":[37,66,147,178,308,337,361],"estimate":[38],"treating":[43],"these":[44,149,363],"United":[48,126],"States.":[49,127],"METHODS:":[50],"A":[51],"cost-estimation":[52],"study":[53,388],"treatment":[58,136,269,373],"was":[62,116,230,265],"conducted":[63],"from":[64,306,335],"2012":[65],"2013":[67],"by":[68],"identifying":[69],"grades":[70],"3":[71],"4":[73],"through":[75],"use":[77],"a":[79],"comprehensive":[80],"search":[81],"drug":[83],"labels":[84],"English-language,":[86],"published":[87],"phase":[88],"2/3":[89],"studies":[90],"PubMed,":[92],"conference":[93],"abstracts,":[94],"National":[97],"Comprehensive":[98],"Cancer":[99],"Network":[100],"guidelines.":[101],"Resource":[102],"utilization":[103],"management":[106],"each":[108,158],"type":[109],"AE":[111,132,160,261,273,295],"outpatient":[114,139,276,379],"setting":[115,140,277],"obtained":[117],"via":[118],"interviews":[119],"5":[121],"specialists":[123],"Unit":[128],"an":[131,272,294],"were":[141,155,193,205,223,244,278,296,327],"assigned":[142],"using":[143,161],"Medicare":[144],"reimbursement":[145],"rates":[146],"obtain":[148],"costs.":[150,364],"Hospitalization":[151],"length-of-stay":[153],"estimated":[156,385],"large":[163],"national":[164],"claims":[165],"database":[166],"Optum":[167],"Clinformatics":[168],"Data":[169],"Mart":[170],"period":[173],"July":[175],"1,":[176],"2004,":[177],"November":[179],"30,":[180],"2012.":[181],"RESULTS:":[182],"The":[183,198,238,256,267,288,340],"most":[184,199,217,231,239,257],"common":[185,200,218,240,258],"chemotherapies":[189],"used":[190],"neutropenia,":[194],"vomiting,":[195,251],"anemia.":[197],"vemurafenib":[204],"cutaneous":[206,224,313],"squamous-cell":[207,225,314],"carcinoma":[208,226],"keratoacanthoma,":[210],"rash,":[211],"elevated":[213,324],"liver":[214,325],"enzymes;":[215],"dabrafenib":[222],"pyrexia.":[228],"Trametinib":[229],"often":[232],"hypertension":[235],"rash.":[237],"ipilimumab":[243],"immune-related":[245],"diarrhea":[246],"colitis,":[248],"dyspnea,":[249],"anemia,":[250,322],"and,":[252],"less":[253],"frequently,":[254],"hypophysitis.":[255],"grade":[259],"3/4":[260],"talimogene":[263],"laherparepvec":[264],"cellulitis.":[266],"highest":[268,289],"neutropenia":[280],"($2092),":[281],"headache":[282],"($609),":[283],"peripheral":[285],"neuropathy":[286],"($539).":[287],"mean":[290,330],"inpatient":[291,381],"acute":[298],"myocardial":[299],"infarction,":[300],"sepsis,":[301],"coma,":[303],"which":[304],"ranged":[305],"$31,682":[307],"$47,069.":[309],"Colitis":[310],"diarrhea,":[312],"carcinoma,":[315],"thrombocytopenia,":[316],"hyponatremia,":[317],"oliguria":[318],"anuria,":[320],"hypertension,":[321],"enzymes":[326],"hospitalization":[333],"ranging":[334],"$19,122":[336],"$26,861.":[338],"CONCLUSION:":[339],"are":[351],"substantial.":[352],"Effective":[353],"treatments":[354],"improved":[356],"safety":[357],"profiles":[358],"may":[359],"help":[360,390],"reduce":[362],"Until":[365],"real-world":[366],"evidence":[367],"toxicity":[374],"is":[375],"available":[376],"settings,":[382],"this":[387],"can":[389],"inform":[391],"decision":[392],"makers":[393],"about":[394],"cost-effectiveness":[396]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":4}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-07-22T00:00:00"}